pone.0248034.s006.tif (676.67 kB)
RORγt-mediated inhibition of IL-17A production in human Th17 cell cultures.
figure
posted on 2021-11-09, 18:32 authored by Steven A. Saenz, Andrea Local, Tiffany Carr, Arvind Shakya, Shivsmriti Koul, Haiqing Hu, Lisa Chourb, Justin Stedman, Jenna Malley, Laura Akullian D’Agostino, Veerabahu Shanmugasundaram, John Malona, C. Eric Schwartz, Lisa Beebe, Meghan Clements, Ganesh Rajaraman, John Cho, Lan Jiang, Alex Dubrovskiy, Matt Kreilein, Roman Shimanovich, Lawrence G. Hamann, Laure Escoubet, J. Michael EllisCell viability of enriched naïve CD4+ T cells from healthy donor PBMC cultured under Th17 cell conditions, for 6 days (differentiation) (A) or enriched human Th17 cells from healthy donor PBMC cultured with IL-23 and IL-1β, for 4 days (maintenance) (B) in the presence of RORγt inhibitors Compound 1, Compound 2 or Compound 3. Data are normalized to and represented as percent of DMSO control. Error bars are representative of 4 individual donors, from 2 independent experiments.
(TIF)
History
Usage metrics
Categories
Keywords
retinoic acid receptorpancreatic ductal adenocarcinomadiv >< pattractive therapeutic targetassociated gene expressionnumerous autoimmune diseasesdelay tumor volumeinhibit th17 differentiationinhibit tumor formationrorγt block th17tumor formationautoimmune disorderstumor growthtumor effectsth17 cellsvivo vitro transcription factorsrorγt inhibitorsrorγt functionsprimary functionpreclinical modelsimmune responsesdependent mannercritical regulator17a production
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC